Glaukos (GKOS) Stock Analysis: AI Score & Alternative Data
GKOS alt-data: revenue climbing, web traffic lagging
Is Glaukos a buy right now? The alternative data says hold. This GKOS stock analysis is built on the 25+ alternative data signals AltIndex tracks on Glaukos every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 49/100: a Hold. The stock trades at $185.04 with a $10B market cap.
The bullish side of the 90-day ledger: revenue up 58.3% YoY to $190M, job postings up 17.5% to 47 open roles, and headcount (according to LinkedIn) up 8.3% to 1K employees. The drag: web traffic down 17.0% to 23K monthly visits. That tension is what keeps the score mid-range.
GKOS’s broader alt-data profile also covers business outlook (68% of employees positive), Facebook followers (7K), and sentiment (50/100). Every signal links to its own page with full history, the GKOS technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on GKOS is just below.
Glaukos AI Stock Analysis
Glaukos Corporation is a pharmaceutical company that specializes in the development and commercialization of novel therapies and devices aiming to enhance the lives of patients suffering from chronic eye diseases. Established as a pioneer in ophthalmic treatment, Glaukos focuses on providing minimally invasive solutions for glaucoma, corneal disorders, and retinal diseases.
Analysis generated September 2, 2026.
Recent Glaukos Stock Alerts
|
Glaukos | August 5 Insider Alert: WEN LEANA is selling shares |
|
Glaukos | August 4 Job postings are up by 26.3% in the last couple of days. |
|
Glaukos | August 1 Job postings are up by 35.5% in the last couple of days. |
|
Glaukos | July 30 Price is up by 6.4% in the last 24h. |
Glaukos Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 23K | 17.0% | |
| Job Posts | 47 | 17.5% | |
| LinkedIn Employees | 1K | 8.3% | |
| Employee Recommend | 70 | 4.1% | |
| Business Outlook | 68 | 4.2% | |
| Sentiment | 50 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 90.9% | |
| Stocktwits Mentions | 1 | 75.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 928 | 1.2% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 2K | 0% | |
| Instagram Followers | 4K | 2.9% | |
| Facebook Followers | 7K | 0% | |
| Facebook Engagement | 15 | 275.0% |
About Glaukos (GKOS)
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
| Price | $185.04 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $10B |
| Year Range | $75 – $190 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Medical Devices |
Latest Glaukos News
View more → |
Glaukos completes patient enrolment in Phase II trial of GLK-321June 26 - Biztoc.com |
 |
Glaukos Stock Surges 18% on Record Q1 Sales Beat and Raised 2026 Outlook as iDose TR Demand SoarsApril 30 - Ibtimes.com.au |
 |
Glaukos outlines $620M-$635M 2026 net sales outlook following Q1 outperformanceApril 29 - Seeking Alpha |
Strong Results with 38.1% Revenue Growth Lifted Glaukos (GKOS) in Q4February 23 - Yahoo Entertainment |
|
Glaukos Corporation Q4 2025 Earnings Call SummaryFebruary 19 - Yahoo Entertainment |
|
See Glaukos’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for GKOS, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEGlaukos Earnings & Financial Performance
View all earnings →Glaukos Insider Trading Activity
View all →| Gilliam Joseph E filed to sell 104,625 shares at $0.0. Aug 11 '26 |
| Gilliam Joseph E filed to sell 72,588 shares at $0.0. Aug 11 '26 |
| Thurman Alex R. filed to sell 43,906 shares at $0.0. Aug 7 '26 |
| WEN LEANA filed to sell 21,092 shares at $0.0. Jul 31 '26 |
| Thurman Alex R. filed to sell 43,906 shares at $0.0. Jul 16 '26 |
Glaukos Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Glaukos
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Globus MedicalGMED |
$75.04 4.2% | $11B | 56 |
 |
InsuletPODD |
$142.28 3.5% | $10B | 49 |
 |
BrukerBRKR |
$58.37 0.2% | $9B | 55 |
 |
PenumbraPEN |
$319.26 0.9% | $13B | 55 |
 |
CooperCompaniesCOO |
$67.69 2.7% | $14B | 43 |
Explore Glaukos Data
Frequently Asked Questions: Glaukos (GKOS)
Glaukos has an AltIndex AI Score of 49/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
49/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Glaukos (GKOS) stock is $185.04 with a market cap of $10B.
As of today, Glaukos’s PE (Price to Earnings) ratio is —.
View the latest Glaukos insider transactions to see recent buying and selling activity by company executives and directors.
Check the Glaukos congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The GKOS stock price chart above shows Glaukos’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Glaukos technical analysis for RSI, moving averages, and more.
See the stocks similar to Glaukos section on this page for companies in the same industry ranked by market cap and AI Score.
